Search clinical trials for: Tacrolimus (Prograf®)

Total 21060 results

University of British Columbia
Simon Fraser University; Astellas Pharma Canada, Inc.

Completed

Comparison of Medication Adherence Between Once and Twice Daily Tacrolimus in Stable Renal Transplant Recipients

Renal Transplant | Renal Disease

Canada
Astellas Pharma Canada, Inc.

Completed

A Comparison of the Effects of Extended Release Tacrolimus (Advagraf®) vs. Immediate Release Tacrolimus (Prograf®) on Kidney Function in Healthy Male Volunteers

Healthy

Canada
Hospital Universitari de Bellvitge

Completed

Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day. (TACPKPD)

Kidney Transplant; Complications

Spain
University Hospital Tuebingen

Completed

Tacrolimus Formulation and Glucose Metabolism After Kidney Transplantation (TAGLUMET Trial) (TAGLUMET)

Posttransplant Diabetes Mellitus

Germany
East Carolina University
Astellas Pharma US, Inc.

Completed

Optima: Optimizing Prograf Therapy in Maintenance Allografts II (OPTIMAII)

Kidney Transplantation

United States
University of Saskatchewan
Astellas Pharma Canada, Inc.

Completed

Evaluation Of Switching From Twice Daily Tacrolimus To Once Daily Formulation On Cardiovascular Risk (ESTTEROD)

Cardiovascular Diseases | Kidney Transplantation | Immunosuppression

Canada
The Second Artillery General Hospital
Capital Medical University; Shanghai Changzheng Hospital; Air Force General Hospital... and other collaborators

Completed

Initial Dosage Range of Tacrolimus by Genotyping in Chinese Renal Transplantation (PSIDRTG)

Renal Transplantation

China
University of Minnesota

Completed

Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (Envarsus® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients

Kidney Transplant Failure and Rejection

United States
Astellas Pharma Inc
Astellas Pharma US, Inc.

Completed

Optimizing Prograf® Therapy in Renal Transplant Patients (OPTIMA)

Renal Transplantation

United States
University of Toledo Health Science Campus
Novartis Pharmaceuticals

Completed

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

Renal Transplant

United States
Chiesi Farmaceutici S.p.A.

Completed

Multicentre, Open Label, Randomized, Two-arm, Parallel-group Study to Assess Efficacy and Safety of ENVARSUS® Compared With Tacrolimus Used as Per Current Clinical Practice in the Initial Maintenance Setting in de Novo Kidney Transplant Patients (STEADY)

End Stage Renal Disease

Italy
Roy D. Bloom, MD
Veloxis Pharmaceuticals

Recruiting

Pulse Wave Velocity, Tacrolimus Time in Therapeutic Range and CV in African American Kidney Transplants (PTAAK)

Kidney Transplant; Complications

United States
Barbara Ann Karmanos Cancer Institute

Completed

Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT

Hematological Malignancies

United States
Assistance Publique - Hôpitaux de Paris

Completed

Conversion Prograf® to Advagraf® at D7 Versus D90 After Liver Transplantation (Conversion)

Immunosuppression After Liver Transplantation

France
Hannover Medical School

Terminated

Twice Daily Versus Once Daily Administration of the Tacrolimus in Lung Transplantation

Lung Transplantation

Germany
Astellas Pharma S.A.S.

Completed

A Study of Renal Transplant Patients Converted From the Twice Per Day Form of Tacrolimus (Prograf®) to the Once Per Day Form (Advagraf®) (OPALE)

Renal Transplantation

France
Astellas Pharma Inc

Completed

A Study to Compare the Conversion to Prograf® (Tacrolimus) to the Continuation of Cyclosporine in Patients at Risk for Chronic Renal Allograft Failure (CRAF)

Kidney Transplantation | Graft Rejection

United States
Astellas Pharma Inc
Astellas Pharma Korea, Inc.

Completed

Pharmacokinetics of Tacrolimus in Liver Transplantation Patients Treated With Prograf and Modified Release Tacrolimus

Liver Transplantation

Korea, Republic of
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics of a Modified-release Tacrolimus Based Immunosuppression Regimen in Stable Kidney Transplant Patients

Kidney Transplantation

United States, Canada
Astellas Pharma Inc

Completed

A Study to Evaluate and Compare the Efficacy and Safety of FK506MR vs Prograf® in Stable Liver Transplantation Patients

Liver Transplantation

China
University Hospital, Limoges

Unknown

PK Assessment of Tacrolimus Exposure Before and After a Switch From Twice Daily Immediate-release (Prograf®) to Once-daily Prolonged Release Tacrolimus (Envarsus®) (ENVARSWITCH)

Allograft

France
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients

Graft Rejection | Kidney Failure

United States, Spain, Canada, Switzerland, Austria, Australia, New Zealand
Technical University of Munich

Completed

PEL-1235_REN-0176-I (Pelicon) (Pelicon)

Immunosuppression After Kidney Transplantation

Germany
Novartis Pharmaceuticals

Completed

A National Multi-center Randomized, Open Label Study to Evaluate Efficacy and Safety of Everolimus With EC-MPS Compared to Standard Treatment Combination Tacrolimus and EC-MPS in de Novo Liver Transplant Recipients (SIMCER)

Liver Transplantation

France
Astellas Pharma Europe Ltd.

Active, not recruiting

Study to Compare the Pharmacokinetics of Tacrolimus in Stable Pediatric Allograft Recipients Converted From Prograf® to Advagraf®

Liver Transplantation | Kidney Transplantation | Heart Transplantation | Lung Transplantation | Intestine Transplantation

Belgium, Czechia, France, Germany, Italy, Poland, United Kingdom
Imperial College Healthcare NHS Trust

Completed

Mycophenolate Mofetil and Tacrolimus Versus Tacrolimus for the Treatment of Idiopathic Membranous Glomerulonephritis (MTAC)

Glomerulonephritis, Membranous

United Kingdom
HK inno.N Corporation

Not yet recruiting

A Study to Evaluate Effect of IN-A001 on Pharmacokinetics of Tacrolimus in Healthy Volunteers

Healthy

Korea, Republic of
University Hospital, Essen

Recruiting

Pharmacokinetics, Effectiveness and Tolerability of Prolonged-release Tacrolimus After Paediatric Kidney Transplantation (Pro-Tac)

Pediatric Kidney Disease

Germany
Novartis Pharmaceuticals

Completed

Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients

Liver Transplant Recipient

Belgium, Spain, Germany, Italy, Australia, United States, Netherlands, Ireland, Sweden, Brazil, Colombia, France, Russian Federation, Argentina, Czechia, United Kingdom
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients (RAD)

Liver Transplantation

United States, Belgium, Colombia, Spain, Germany, Italy, Australia, Israel, France, Hungary, Netherlands, Argentina, Canada, Ireland, Sweden, Brazil, United Kingdom, Russian Federation, Czech Republic
Novartis
Sandoz

Completed

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

Renal Transplant

United States
Astellas Pharma Korea, Inc.

Completed

A Single Center, Open-label, Randomized, Pilot Study to Evaluate the Safety and Efficacy of a Tacrolimus Modified Release, ADVAGRAF®, Versus Tacrolimus Twice Daily, PROGRAF® in Stable Renal Recipients (SINGLE)

Kidney Transplantation | Renal Transplantation | Stable Renal Recipients

Korea, Republic of
Astellas Pharma Europe Ltd.

Terminated

A Paediatric, Open, Follow up Study With Modigraf Examining Safety and Efficacy in de Novo Allograft Recipients (PROGRESSION)

Liver Transplantation | Kidney Transplantation | Heart Transplantation

Belgium, France, Germany, Poland, Spain, United Kingdom
Chong Kun Dang Pharmaceutical

Unknown

Study to Evaluate the Pharmacokinetics and Tolerability of Tacrolimus in Kidney Transplant Recipients. (PK-TACT)

Kidney Transplant

Korea, Republic of
Kasr El Aini Hospital

Completed

Efficiency of Fractional-Laser Resurfacing Followed by Topical Tacrolimus 0.03% Cream vs Tacrolimus Alone in Vitiligo

Stable Vitiligo
Astellas Pharma Inc

Completed

A Study to Assess the Pharmacokinetics, Safety and Efficacy of Advagraf and Prograf in de Novo Liver Transplantation (MAIN)

Liver Transplantation

Korea, Republic of
Veloxis Pharmaceuticals

Completed

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

Renal Failure

United States
University of Cincinnati
University of Colorado, Denver; Children's Hospital Medical Center, Cincinnati

Completed

Pharmacokinetic Studies of Tacrolimus in Transplant Patients (PK)

Liver Transplant Recipients | Kidney Transplant Recipients

United States
Astellas Pharma Korea, Inc.

Completed

A Study to Assess the Safety and Efficacy of ADVAGRAF (Tacrolimus Modified Release Formulation) in Kidney Transplant Patients Who Were Treated With PROGRAF (PeACE)

Kidney Transplantation

Korea, Republic of
University of British Columbia
Paladin Labs Inc.

Recruiting

Tacrolimus Associated Tremors in Liver Transplantation: Immediate-Release Versus Extended-Release Formulations (LCP-TAC)

Liver Transplantation | Neurotoxicity | Tremor | Tacrolimus | Immunosuppression

Canada
Nanjing University School of Medicine

Withdrawn

Tacrolimus Treatment of Patients With Idiopathic Focal Segmental Glomerulosclerosis

Focal Glomerulosclerosis

China
NYU Langone Health

Completed

Envarsus XR in Lung Transplant

Lung Transplant

United States
Astellas Pharma Inc

Completed

Study to Compare the Pharmacokinetics of Tacrolimus in Adult Transplant Recipients Treated With Advagraf® or Prograf®

Heart Transplantation | Lung Transplantation | Pancreas (Including SPK) Transplantation

France, United Kingdom, Taiwan, Belgium, Italy, Austria
Veloxis Pharmaceuticals

Completed

Double-Blind,Double-Dummy,Efficacy/Safety,LCP-Tacro™ Vs Prograf®,Prevention Rejection,De Novo Adult Kidney Tx (LCPTacro3002)

Renal Failure

United States, Argentina, Australia, Brazil, France, Germany, Italy, Korea, Republic of, Mexico, New Zealand, Poland, Serbia, Singapore, Spain, Sweden
Astellas Pharma Korea, Inc.

Terminated

A Study to Evaluate the Efficacy and Safety of Tacrolimus With Steroid in Korean Lupus Nephritis Patients (APPLE)

Lupus Nephritis

Korea, Republic of
Astellas Pharma Inc

Completed

An Open Study for Steroid Resistant, Non-Thymectomized MG Patients

Myasthenia Gravis

Japan
Vastra Gotaland Region

Completed

A 1-year Comparison of Generic Tacrolimus (Tacni) and Prograf in Renal Transplant Patients - a Retrospective Matched Pair Analysis, GenTac (GenTac)

Renal Transplantation

Sweden
Veloxis Pharmaceuticals
CTI Clinical Trial and Consulting Services

Completed

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

Renal Failure

United States
Astellas Pharma Inc

Completed

A Survey for Long-term Use of Prograf Capsules in Patient With Interstitial Pneumonia

Interstitial Pneumonia Associated With Polymyositis/Dermatomyositis

Japan
Seoul National University Hospital

Completed

Conversion of Prograf to Advagraf in Pediatric Renal Transplant Recipients

Kidney Transplantation | Pediatric Patients | Maintenance With Tacrolimus

Korea, Republic of

3

Subscribe